Effectiveness and Safety of Weekly Adalimumab for Non-Infectious Chronic Anterior Uveitis in Children

References

• Kouwenberg CV, Wennink RAW, Shahabi M, et al. Clinical course and outcome in pediatric idiopathic chronic anterior uveitis. Am J Ophthalmol. 2022;241:198–205. doi:10.1016/j.ajo.2022.04.015.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B, Wouters C, Job-Deslandre C, et al. Recommandations pour la prise en charge des formes oligoarticulaire et polyarticulaires (en dehors de la polyarthrite rhumatoïde) d’arthrite juvénile idiopathique [Guidelines for diagnosis and treatment of oligoarticular and polyarticular juvenile idiopathic arthritis]. Archives de Pédiatrie. 2010;17(7):1085–1089. doi:10.1016/j.arcped.2010.04.002.
   PubMed Web of Science ®Google Scholar
• Marvillet I, Terrada C, Quartier P, et al. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine. 2009;76(4):383–388. doi:10.1016/j.jbspin.2008.10.015.
   PubMed Web of Science ®Google Scholar
• Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):281–290. doi:10.1007/s00417-005-0087-3.
   PubMed Web of Science ®Google Scholar
• Holland GN, Denove CS, Yu F. Chronic anterior uveitis in children: clinical characteristics and complications. Am J Ophthalmol. 2009;147(4):667–678.e665. doi:10.1016/j.ajo.2008.11.009.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I. Pediatric uveitis. J Ophthalmic Vis Res. 2011;6:259–269.
   PubMedGoogle Scholar
• Ferrara M, Eggenschwiler L, Stephenson A, et al. The challenge of pediatric uveitis: tertiary referral center experience in the United States. Ocul Immunol Inflamm. 2019;27(3):410–417. doi:10.1080/09273948.2017.1420202.
   PubMed Web of Science ®Google Scholar
• Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis–related uveitis. J Aapos. 2008;12(6):539–545. doi:10.1016/j.jaapos.2008.03.007.
   PubMed Web of Science ®Google Scholar
• Wu PY, Kang EY, Chen WD, et al. Epidemiology, treatment, and outcomes of juvenile idiopathic arthritis-associated uveitis: a multi-institutional study in Taiwan. Ocul Immunol Inflamm. 2023;1–9. doi:10.1080/09273948.2022.2162927.
   Web of Science ®Google Scholar
• Kardes E, Sözeri B, Demir F, Sezgin Akcay BI. Risk factors for ocular complications and visual loss in patients with juvenile idiopathic arthritis-associated uveitis at a Turkish tertiary ophthalmology and pediatric rheumatology referral center. Ocul Immunol Inflamm. 2022;1–8. doi:10.1080/09273948.2022.2123833.
   PubMed Web of Science ®Google Scholar
• Rutkowska-Sak L, Gietka P. Uveitis associated juvenile idiopathic arthritis – presentation of recently published international recommendations for diagnostic and therapeutic procedures. Reumatologia. 2020;58(5):277–281. doi:10.5114/reum.2020.100169.
   PubMedGoogle Scholar
• Cann M, Ramanan AV, Crawford A, et al. Outcomes of non-infectious paediatric uveitis in the era of biologic therapy. Pediatr Rheumatol Online J. 2018;16(1):51. doi:10.1186/s12969-018-0266-5.
   PubMed Web of Science ®Google Scholar
• Tirelli F, Zannin ME, Vittadello F, et al. Methotrexate monotherapy in juvenile idiopathic arthritis associated uveitis: myth or reality? Ocul Immunol Inflamm. 2022;30(7–8):1763–1767. doi:10.1080/09273948.2021.1951303.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Touhami S, Quartier P, Bodaghi B. Therapeutic advances in juvenile idiopathic arthritis - associated uveitis. Curr Opin Ophthalmol. 2019;30(3):179–186. doi:10.1097/icu.0000000000000559.
   PubMed Web of Science ®Google Scholar
• Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003–1011. doi:10.1136/annrheumdis-2017-212089.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646. doi:10.1056/NEJMoa1614160.
   PubMed Web of Science ®Google Scholar
• Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti–tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014;66(7):1073–1084. doi:10.1002/acr.22214.
   PubMed Web of Science ®Google Scholar
• Ming S, Xie K, He H, Li Y, Lei B. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005–2016. doi:10.2147/dddt.S160431.
   PubMed Web of Science ®Google Scholar
• Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77:1107–1117. doi:10.1136/annrheumdis-2018-213131.
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis–associated uveitis. Arthritis Care Res (Hoboken). 2019;71(6):703–716. doi:10.1002/acr.23871.
   PubMed Web of Science ®Google Scholar
• Chen JL, Abiri P, Tsui E. Recent advances in the treatment of juvenile idiopathic arthritis-associated uveitis. Ther Adv Ophthalmol. 2021;13:2515841420984572. doi:10.1177/2515841420984572.
   Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516. doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Quartier P. Juvenile idiopathic arthritis-associated chronic uveitis: recent therapeutic approaches. J Clin Med. 2021;10(13):2934. doi:10.3390/jcm10132934.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Klotsche J, Sengler C, et al. Risk factors and biomarkers for the occurrence of uveitis in juvenile idiopathic arthritis: data from the inception cohort of newly diagnosed patients with juvenile idiopathic arthritis study. Arthritis Rheumatol. 2018;70(10):1685–1694. doi:10.1002/art.40544.
   PubMed Web of Science ®Google Scholar
• Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm. 2013;21(6):478–485. doi:10.3109/09273948.2013.815785.
   PubMed Web of Science ®Google Scholar
• Karakosta A, Vassilaki M, Plainis S, et al. Choice of analytic approach for eye-specific outcomes: one eye or two? Am J Ophthalmol. 2012;153(3):571–579.e571. doi:10.1016/j.ajo.2011.08.032.
   PubMed Web of Science ®Google Scholar
• Fan Q, Teo YY, Saw SM. Application of advanced statistics in ophthalmology. Invest Ophthalmol Vis Sci. 2011;52(9):6059–6065. doi:10.1167/iovs.10-7108.
   PubMed Web of Science ®Google Scholar
• Altemir I, Pueyo V, Elía N, et al. Reproducibility of optical coherence tomography measurements in children. Am J Ophthalmol. 2013;155(1):171–176.e171. doi:10.1016/j.ajo.2012.06.012.
   PubMed Web of Science ®Google Scholar
• Al-Haddad C, Barikian A, Jaroudi M, et al. Spectral domain optical coherence tomography in children: normative data and biometric correlations. BMC Ophthalmol. 2014;14(1):53. doi:10.1186/1471-2415-14-53.
   PubMedGoogle Scholar
• Barrio-Barrio J, Noval S, Galdós M, et al. Multicenter Spanish study of spectral-domain optical coherence tomography in normal children. Acta Ophthalmol. 2013;91(1):e56–63. doi:10.1111/j.1755-3768.2012.02562.x.
   PubMed Web of Science ®Google Scholar
• van Meerwijk C, Wieringa WG, de Boer JH, Jansonius NM, Los LI. Factors associated with glaucoma surgery in pediatric non-infectious uveitis. Ocul Immunol Inflamm. 2023;1–6. doi:10.1080/09273948.2023.2166849.
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos D, Kalogeropoulos C, Moschos MM, Sung V. The management of uveitic glaucoma in children. Turk J Ophthalmol. 2019;49(5):283–293. doi:10.4274/tjo.galenos.2019.36589.
   PubMedGoogle Scholar
• Gautam Seth N, Yangzes S, Thattaruthody F, et al. Glaucoma secondary to uveitis in children in a tertiary care referral center. Ocul Immunol Inflamm. 2019;27(3):456–464. doi:10.1080/09273948.2017.1411517.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–1441. doi:10.1016/j.ophtha.2009.12.003.
   PubMed Web of Science ®Google Scholar
• Wolf D, D’Haens G, Sandborn WJ, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014;40(5):486–497. doi:10.1111/apt.12863.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167(3):658–667. doi:10.1111/j.1365-2133.2012.11041.x.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Rosh J, Faubion WA Jr., et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with crohnʼs disease. Inflamm Bowel Dis. 2016;22(4):886–893. doi:10.1097/mib.0000000000000715.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for crohnʼs disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011;17(1):141–151. doi:10.1002/ibd.21328.
   PubMed Web of Science ®Google Scholar
• Liberman P, Berkenstock MK, Burkholder BM, Chaon BC, Thorne JE. Escalation to weekly adalimumab for the treatment of ocular inflammation. Ocul Immunol Inflamm. 2021;29(7–8):1564–1568. doi:10.1080/09273948.2020.1749857.
   PubMed Web of Science ®Google Scholar
• Lee J, Koreishi AF, Zumpf KB, Minkus CL, Goldstein DA. Success of weekly adalimumab in refractory ocular inflammatory disease. Ophthalmology. 2020;127(10):1431–1433. doi:10.1016/j.ophtha.2020.04.009.
   PubMed Web of Science ®Google Scholar
• Roberts JE, Nigrovic PA, Lo MS, Chang MH. Weekly adalimumab, an effective alternative for refractory uveitis in children. J Clin Rheumatol. 2022;28(1):e301–e304. doi:10.1097/rhu.0000000000001707.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019;49(1):43–55. doi:10.1016/j.semarthrit.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Heiligenhaus A, deBoer J, Cunningham ET, Tugal-Tutkun I. Controversies in juvenile idiopathic arthritis-associated uveitis. Ocul Immunol Inflamm. 2013;21(3):167–179. doi:10.3109/09273948.2013.800561.
   PubMed Web of Science ®Google Scholar
• Kothari S, Foster CS, Pistilli M, et al. The risk of intraocular pressure elevation in pediatric noninfectious uveitis. Ophthalmology. 2015;122(10):1987–2001. doi:10.1016/j.ophtha.2015.06.041.
   PubMed Web of Science ®Google Scholar
• Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52(5):825–831. doi:10.1093/rheumatology/kes186.
   PubMed Web of Science ®Google Scholar
• Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46. doi:10.1186/s12969-018-0255-8.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. doi:10.1186/s13063-021-05651-5.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143(5):840–846. doi:10.1016/j.ajo.2007.01.033.
   PubMed Web of Science ®Google Scholar
• Mastrangelo G, Foeldvari I, Anton J, Simonini G. Defining outcome measures in juvenile idiopathic arthritis associated uveitis by a systematic review analysis: do we need a consensus? Pediatr Rheumatol Online J. 2019;17(1):40. doi:10.1186/s12969-019-0330-9.
   PubMedGoogle Scholar
• Wakefield D, Herbort CP, Tugal-Tutkun I, Zierhut M. Controversies in ocular inflammation and immunology laser flare photometry. Ocul Immunol Inflamm. 2010;18(5):334–340. doi:10.3109/09273948.2010.512994.
   PubMed Web of Science ®Google Scholar
• Holland GN. A reconsideration of anterior chamber flare and its clinical relevance for children with chronic anterior uveitis (an American ophthalmological society thesis). Trans Am Ophthalmol Soc. 2007;105:344–364.
   PubMedGoogle Scholar
• Miraldi Utz V, Angeles-Han ST, Mwase N, et al. Alternative biologic therapy in children failing conventional TNFα inhibitors for refractory, noninfectious, chronic anterior uveitis. Am J Ophthalmol. 2022;244:183–195. doi:10.1016/j.ajo.2022.06.024.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Klotsche J, Niewerth M, et al. Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. Arthritis Res Ther. 2020;22(1):81. doi:10.1186/s13075-020-02166-3.
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis–associated and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken). 2019;71(4):482–491. doi:10.1002/acr.23610.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–820. doi:10.1056/NEJMoa0706290.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Takei S, Umebayashi H, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012;31(12):1713–1721. doi:10.1007/s10067-012-2082-5.
   PubMed Web of Science ®Google Scholar
• Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20(4):431–435. doi:10.1016/j.coi.2008.06.011.
   PubMed Web of Science ®Google Scholar
• Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37(2):549–553. doi:10.1007/s10067-017-3890-4.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Xie F, Chen L, et al. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis. 2018;77(7):1012–1016. doi:10.1136/annrheumdis-2017-212613.
   PubMed Web of Science ®Google Scholar
• Horne A, Delcoigne B, Palmblad K, Askling J. Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies. RMD Open. 2019;5(2):e001055. doi:10.1136/rmdopen-2019-001055.
   PubMed Web of Science ®Google Scholar
• Mannion ML, Beukelman T. Risk of malignancy associated with biologic agents in pediatric rheumatic disease. Curr Opin Rheumatol. 2014;26(5):538–542. doi:10.1097/bor.0000000000000090.
   PubMed Web of Science ®Google Scholar
• Maccora I, dell’ Anna MP, Vannacci A, Simonini G. Safety evaluations of adalimumab for childhood chronic rheumatic diseases. Expert Opin Drug Saf. 2020;19(6):661–671. doi:10.1080/14740338.2020.1763300.
   PubMed Web of Science ®Google Scholar